Developing Fluorescent Biomarkers to 
Improve
Patient Outcomes

Our Mission: To become the world leader in fluorescence based diagnostics and surgical support.

Cancer removal is challenging ... 

Lung Cancer:

Picture1.png

... and incomplete removal leads to recurrence. 

Picture1b.png
Picture1a.png
Colorectal Cancer:
Cervical Cancer:
Picture2.png

Reiner et al. Neoplasia 2012, 14:169–17.

But using fluorescent biomarkers allows clinicians to more effectively find and remove cancer.

Our proprietary technology is a fluorescent small molecule, PARPi-FL, that detects overexpression of PARP, a DNA repair enzyme, which is common in many cancers. Thus, our technology specifically targets oral cancer, enabling earlier, more accurate detection.

Technology_SchematicOverview.001.png

Summit is developing fluorescent biomarkers that target PARP, an enzyme that is over expressed by many cancers.

Picture3.png
Screen Shot 2022-09-01 at 4.38.49 PM.png

Tang et al. (2017) PNAS and unpublished data. 

Thurber et al. Nat Commun 2013, 4, 1504.

Pipeline

Initial development targets:

         PARPi-FL for margin detection (head & neck, cervical, skin, colorectal)

         SBI-002 for fluorescence guided surgery (breast)

Picture1d.png